⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 17, 2025

Supplemental Fig S3 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Funda Meric‐Bernstam Martin Gutierrez Enrique Sanz‐García Diego Villa Jun Zhang Jennifer Friedmann Fengting Yan Mark A. Socinski John Sarantopoulos Luis E. Raez Quincy S. Chu Maxime Chénard-Poirier Manash S. Chatterjee Hong Ren Qi Liu Douglas A. Levine Komal Jhaveri

View at Publisher

Ask AI

Bookmark

Share

Key Points

Zilovertamab vedotin shows promise in treating metastatic solid tumors during phase 2 study.
Important metrics include response events and participant disposition throughout the treatment.
The study utilizes swimlane plots to visualize treatment responses effectively.
Findings may inform future therapeutic approaches for patients with advanced cancer.

Implication

Phase 2 study reports response events and treatment disposition in participants, indicating zilovertamab's potential effectiveness.

Abstract

Supplemental Fig S3. Swimlane Plots for Response Events and Disposition During Study Treatment per BICR

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Meric‐Bernstam et al. (2025) studied this question.

synapsesocial.com/papers/68d462b631b076d99fa61b02 https://doi.org/10.1158/2767-9764.30146517

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Fig S4 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
2Supplemental Table S4 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
3Supplemental Fig S8 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
4Supplemental Fig S5 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
5Supplemental Fig S9 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025

More related papers

Supplemental Fig S6 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
Supplemental Fig S7 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
Supplemental Table S2 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025